New Lung Cancer Treatment: IDEAYA Seeks FDA Approval for Targeted Therapy IDE892

In this episode, we explore IDEAYA Biosciences’ request for FDA approval to begin clinical testing of IDE892, a new targeted therapy designed for patients with MTAP-deleted non-small cell lung cancer (NSCLC). This potential breakthrough drug represents a step forward in precision cancer treatment. You’ll learn: What IDE892 is and how it works as a PRMT5 inhibitorWhy MTAP-deleted NSCLC patients could benefit most from this treatmentHow Phase 1 clinical trials will test safety, dosing, and earl...